Probiotics in diverticular disease of the colon: an open label study.
OBJECTIVE
To investigate the effectiveness and safety of a symbiotic mixture in preventing recurrence of constipation-related abdominal pain in patients with uncomplicated diverticular disease of the colon.


METHODS
Forty-six consecutive patients (10 men, 36 women, mean age 62.5 years, range 49 to 77 years), previously affected by symptomatic uncomplicated diverticular disease of the colon, were enrolled in a 6-month follow-up study in a prospective, randomized, open-label study. The following symptoms were assessed at entry and through follow-up by using a quantitative scale: constipation, diarrhoea and abdominal pain. After recruitment, the patients were assigned to the following treatment: SCM-III symbiotic mixture, 10 ml three times a day. The colonization of ingested Lactobacillus acidophilus 145 and Bifidobacterium spp. 420 was assessed by species-specific PCR. Forty-five patients completed the study (97%).


RESULTS
Thirty-one patients (68%) were still symptom free after the 6th month of treatment. Treatment with SCM-III was regarded as "effective" or "very effective" in more than 78% of the patients altogether (p<0.01 vs baseline values). The microbiological study showed that, as compared to baseline values, SCM-III enabled a significant increase of the lactobacilli and bifidobacteria counting and a trend decrease of clostridia. Genomic analysis confirmed the survivability of the ingested strain as long as treatment was given.


CONCLUSIONS
The present symbiotic mixture seems to be effective in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon, especially in those patients with constipation-predominant features.
Lamiki
Pepu
P
TMC Hospital, Shizuoka, Japan.
Tsuchiya
Junji
J
Pathak
Surajit
S
Okura
Ruichi
R
Solimene
Umberto
U
Jain
Shalini
S
Kawakita
Shichiro
S
Marotta
Francesco
F
D015746:Abdominal Pain / Q000209:etiology / Q000382:microbiology / Q000628:therapy*; D000368:Aged; D001644:Bifidobacterium / Q000235:genetics / Q000254:growth & development*; D003106:Colon / Q000382:microbiology*; D003248:Constipation / Q000209:etiology / Q000382:microbiology / Q000628:therapy*; D004269:DNA, Bacterial / Q000302:isolation & purification; D004241:Diverticulum, Colon / Q000150:complications / Q000382:microbiology / Q000628:therapy*; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007779:Lactobacillus acidophilus / Q000235:genetics / Q000254:growth & development*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D019936:Probiotics / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
D004269:DNA, Bacterial